Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDH17 CAR-T in advanced solid tumors
NCT06820424Phase 1Recruiting
- Start
- Mar 2025
- Primary completion
- Jan 2028
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CHM-2101 in solid tumor. Primary endpoint: Incidence of adverse events at 52 weeks. Started Mar 2025; status: recruiting.
02
Drugs
CHM-2101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06820424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06820424.